Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers

[1]  W. Monteiro,et al.  Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.

[2]  F. Nosten,et al.  Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria , 2019, The New England journal of medicine.

[3]  M. Fukuda,et al.  Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure , 2018, International Ophthalmology.

[4]  I. Mueller,et al.  The Biology of Plasmodium vivax. , 2017, Cold Spring Harbor perspectives in medicine.

[5]  S. Kochar,et al.  Retinopathy of vivax malaria in adults and its relation with severity parameters , 2016, Pathogens and global health.

[6]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[7]  S. Krudsood,et al.  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.

[8]  R. Kirubakaran,et al.  Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine. , 2013, The Cochrane database of systematic reviews.

[9]  P. Leggat,et al.  Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects , 2009, Antimicrobial Agents and Chemotherapy.